Patents by Inventor Francois Gaudet

Francois Gaudet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI- GPRC5D ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND GPRC5D AND CD3, AND USES THEREOF
    Publication number: 20240343796
    Abstract: Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.
    Type: Application
    Filed: December 4, 2023
    Publication date: October 17, 2024
    Inventors: Ricardo Attar, Francois Gaudet, Mark Tornetta, Alexey Teplyakov, Mark Mendonca, Suzanne Edavettal, Kodandaram Pillarisetti, Nathan Majewski, Yingzhe Li, Leopoldo L. Luistro, III, Diana Chin
  • COMPOSITIONS COMPRISING A T CELL REDIRECTION THERAPEUTIC AND A VLA-4 ADHESION PATHWAY INHIBITOR
    Publication number: 20240327514
    Abstract: Disclosed herein is a pharmaceutical composition comprising a T cell redirect therapeutic and a VLA-4 adhesion pathway inhibitor, and uses thereof for killing cancer cells.
    Type: Application
    Filed: February 2, 2024
    Publication date: October 3, 2024
    Inventors: Priyanka Nair-Gupta, François Gaudet
  • METHODS OF TREATING CANCERS AND ENHANCING EFFICACY OF T CELL REDIRECTING THERAPEUTICS
    Publication number: 20240301083
    Abstract: Disclosed are methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics.
    Type: Application
    Filed: May 7, 2024
    Publication date: September 12, 2024
    Inventors: Homer Adams, Francois Gaudet, Niels Van de Donk, Kris Frerichs, Christie Verkleij
  • GPRC5D chimeric antigen receptors and cells expressing the same
    Patent number: 12077592
    Abstract: The present disclosure provides for chimeric antigen receptors (CARs) that specifically target a G-protein coupled receptor, G-protein coupled receptor family C group 5 member D (GPRC5D), and immunoresponsive cells comprising such CARs, for the treatment of cancer.
    Type: Grant
    Filed: January 15, 2020
    Date of Patent: September 3, 2024
    Assignee: Janssen Biotech, Inc.
    Inventors: Ricardo Attar, Rajkumar Ganesan, Francois Gaudet, Bradley J. Heidrich, Carmen Baca Jones, John Lee, Yingzhe Li, Sanjaya Singh, Sathya Venkataramani
  • Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics
    Patent number: 12065500
    Abstract: Disclosed are methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: August 20, 2024
    Assignees: Janssen Biotech, Inc., Stichting VUmc
    Inventors: Homer Adams, Francois Gaudet, Niels Van de Donk, Kris Frerichs, Christie Verkleij
  • GPRC5D CHIMERIC ANTIGEN RECEPTORS AND CELLS EXPRESSING THE SAME
    Publication number: 20240262921
    Abstract: The present disclosure provides for chimeric antigen receptors (CARs) that specifically target a G-protein coupled receptor, G-protein coupled receptor family C group 5 member D (GPRC5D), and immunoresponsive cells comprising such CARs, for the treatment of cancer.
    Type: Application
    Filed: April 23, 2024
    Publication date: August 8, 2024
    Inventors: Ricardo ATTAR, Rajkumar Ganesan, Francois Gaudet, Bradley J. Heidrich, Carmen Baca Jones, John Lee, Yingzhe Li, Sanjaya Singh, Sathya Venkataramani
  • COMPOSITIONS COMPRISING A T CELL REDIRECTION THERAPEUTIC AND AN ANTI-CD44 THERAPEUTIC
    Publication number: 20240228618
    Abstract: Disclosed herein is a pharmaceutical composition comprising a T cell redirect therapeutic and an anti-CD44 therapeutic, and uses thereof for killing cancer cells.
    Type: Application
    Filed: May 16, 2022
    Publication date: July 11, 2024
    Inventors: Bradley J. Heidrich, Priyanka Nair-Gupta, Francois Gaudet
  • Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics
    Patent number: 12012461
    Abstract: Disclosed are methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: June 18, 2024
    Assignees: Janssen Biotech, Inc., Stichting VUmc
    Inventors: Homer Adams, Francois Gaudet, Niels Van de Donk, Kris Frerichs, Christie Verkleij
  • METHODS OF TREATING CANCERS AND ENHANCING EFFICACY OF T CELL REDIRECTING THERAPEUTICS
    Publication number: 20240101697
    Abstract: Disclosed are methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics.
    Type: Application
    Filed: June 12, 2023
    Publication date: March 28, 2024
    Inventors: Homer Adams, Francois Gaudet, Niels Van de Donk, Kris Frerichs, Christie Verkleij
  • Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof
    Patent number: 11884722
    Abstract: Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.
    Type: Grant
    Filed: January 20, 2023
    Date of Patent: January 30, 2024
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Ricardo Attar, Francois Gaudet, Mark Tornetta, Alexey Teplyakov, Mark Mendonca, Suzanne Edavettal, Kodandaram Pillarisetti, Nathan Majewski, Yingzhe Li, Leopoldo L. Luistro, III, Diana Chin
  • ANTI-CD3 ANTIBODIES AND USES THEREOF
    Publication number: 20230322924
    Abstract: The present invention relates to antibodies that specifically bind CD3. The present invention relates to antibodies that specifically bind PSMA. The present invention relates to antibodies that specifically bind CD3 and PSMA. The invention relates to antibodies that specifically bind IL1RAP. The present invention relates to antibodies that specifically bind CD33. The present invention relates to antibodies that specifically bind CD3 and IL1RAP. The present invention relates to antibodies that specifically bind CD3 and CD33. The present invention relates to antibodies that specifically bind TMEFF2. The present invention relates to antibodies that specifically bind CD3 and TMEFF2. The present invention relates to fragments of the antibodies, polynucleotides encoding the antibodies or fragments thereof, and methods of making and using the same.
    Type: Application
    Filed: March 8, 2023
    Publication date: October 12, 2023
    Inventors: Francois Gaudet, Jill Giles-Komar, Bradley Heidrich, Chichi Huang, Colleen Kane, Ronan Mcdaid, Jennifer Nemeth-Seay
  • ANTI- GPRC5D ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND GPRC5D AND CD3, AND USES THEREOF
    Publication number: 20230227548
    Abstract: Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.
    Type: Application
    Filed: January 20, 2023
    Publication date: July 20, 2023
    Inventors: Ricardo Attar, Francois Gaudet, Mark Tornetta, Alexey Teplyakov, Mark Mendonca, Suzanne Edavettal, Kodandaram Pillarisetti, Nathan Majewski, Yingzhe Li, Leopoido Luistro, Diana Chin
  • Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof
    Patent number: 11685777
    Abstract: Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: June 27, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Ricardo Attar, Francois Gaudet, Mark Tornetta, Alexey Teplyakov, Mark Mendonca, Suzanne Edavettal, Kodandaram Pillarisetti, Nathan Majewski, Yingzhe Li, Leopoldo L. Luistro, III, Diana Chin
  • ANTI- GPRC5D ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND GPRC5D AND CD3, AND USES THEREOF
    Publication number: 20230084967
    Abstract: Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.
    Type: Application
    Filed: February 3, 2020
    Publication date: March 16, 2023
    Inventors: Ricardo Attar, Francois Gaudet, Mark Tornetta, Mark Mendonca, Suzanne Edavettal, Kodandaram Pillarisetti, Nathan Majewski, Yingzhe Li, Yingzhe Li, Leopoldo Luistro, Diana Chin
  • Anti-CD3 antibodies and uses thereof
    Patent number: 11603405
    Abstract: The present invention relates to antibodies that specifically bind CD3. The present invention relates to antibodies that specifically bind PSMA. The present invention relates to antibodies that specifically bind CD3 and PSMA. The present invention relates to antibodies that specifically bind IL1RAP. The present invention relates to antibodies that specifically bind CD33. The present invention relates to antibodies that specifically bind CD3 and IL1RAP. The present invention relates to antibodies that specifically bind CD3 and CD33. The present invention relates to antibodies that specifically bind TMEFF2. The present invention relates to antibodies that specifically bind CD3 and TMEFF2. The present invention relates to fragments of the antibodies, polynucleotides encoding the antibodies or fragments thereof, and methods of making and using the same.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: March 14, 2023
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Francois Gaudet, Jill Giles-Komar, Bradley Heidrich, Chichi Huang, Colleen Kane, Ronan McDaid, Jennifer Nemeth-Seay
  • Anti-CD33 antibodies, anti-CD33/anti-CD3 bispecific antibodies and uses thereof
    Patent number: 11466082
    Abstract: Anti-CD33 antibodies and antigen-binding fragments thereof and anti-CD33/anti-CD3 bispecific antibodies or antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as cancer.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: October 11, 2022
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Michael Diem, Francois Gaudet, Ronan McDaid, Priyanka Nair-Gupta
  • COMPOSITIONS COMPRISING A T CELL REDIRECTION THERAPEUTIC AND A VLA-4 ADHESION PATHWAY INHIBITOR
    Publication number: 20210363252
    Abstract: Disclosed herein is a pharmaceutical composition comprising a T cell redirect therapeutic and a VLA-4 adhesion pathway inhibitor, and uses thereof for killing cancer cells.
    Type: Application
    Filed: May 18, 2021
    Publication date: November 25, 2021
    Inventors: Priyanka Nair-Gupta, François Gaudet
  • Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof
    Patent number: 10844122
    Abstract: Provided herein are isolated CD3×PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof wherein a FN3 domain specifically binds human prostate specific membrane antigen (PSMA) and a second antigen-binding site immunospecifically binds CD3. Also described are fusion proteins and related polynucleotides capable of encoding the provided fusion proteins and, cells expressing the provided fusion proteins. In addition, methods of using the provided isolated CD3×PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof are described.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: November 24, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: Glenn Anderson, Rosa Cardoso, Michael Diem, Francois Gaudet, Shalom Goldberg, Benjamin Harman, Linus Hyun, Steven Jacobs, Donna Klein, Yingzhe Li, Jinquan Luo, Ronan McDaid, Jill Mooney, Jennifer Nemeth-Seay, Karyn O'Neil, Steven Pomerantz, Galla Chandra Rao, Tracy Spinka-Doms, Alexey Teplyakov, Leopoldo Luistro, Sheng-Jiun Wu
  • GPRC5D CHIMERIC ANTIGEN RECEPTORS AND CELLS EXPRESSING THE SAME
    Publication number: 20200231686
    Abstract: The present disclosure provides for chimeric antigen receptors (CARs) that specifically target a G-protein coupled receptor, G-protein coupled receptor family C group 5 member D (GPRC5D), and immunoresponsive cells comprising such CARs, for the treatment of cancer.
    Type: Application
    Filed: January 15, 2020
    Publication date: July 23, 2020
    Inventors: Ricardo Attar, Rajkumar Ganesan, Francois Gaudet, Bradley J. Heidrich, Carmen Baca Jones, John Lee, Yingzhe Li, Sanjaya Singh, Sathya Venkataramani
  • METHODS OF TREATING CANCERS AND ENHANCING EFFICACY OF T CELL REDIRECTING THERAPEUTICS
    Publication number: 20200190205
    Abstract: Disclosed are methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics.
    Type: Application
    Filed: May 15, 2019
    Publication date: June 18, 2020
    Inventors: Homer Adams, Francois Gaudet, Niels Van de Donk, Kris Frerichs, Christie Verkleij